OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine

OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine
OncBioMune Pharmaceuticals soon will initiate a Phase 2 trial evaluating the effectiveness and safety of its lead immunotherapy, ProscaVax, for men with early-stage prostate cancer. In a recent update, the company announced that the initial installments needed for the study have been made, and final preparations for patient enrollment are being completed. The Phase 2 study (NCT03579654) will be conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, and it will be supervised by Theradex Oncology. “Our excitement is growing as we draw closer to enrollment. We (our company and the host hospital) have already fielded inquiries from prostate cancer patients interested in participating in the study, which is an encouraging sign about recruitment once the trial is opened,” Jonathan Head, PhD, CEO at OncBioMune, said in a press release. ProscaVax is an anti-cancer vaccine being investigated for the treatment of prostate cancer. It consists of a combination of the prostate specific antigen (PSA), a hallmark of prostate cancer, plus two immune system activators, interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). In a prior Phase 1a/1b study (<
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *